Marizyme Stock Current Valuation
| MRZM Stock | USD 0.05 0.00 0.00% |
Valuation analysis of Marizyme helps investors to measure Marizyme's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Marizyme's price fluctuation is out of control at this time. Calculation of the real value of Marizyme is based on 3 months time horizon. Increasing Marizyme's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Marizyme otc stock is determined by what a typical buyer is willing to pay for full or partial control of Marizyme. Since Marizyme is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Marizyme OTC Stock. However, Marizyme's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.05 | Real 0.0365 | Hype 0.05 | Naive 0.0393 |
The intrinsic value of Marizyme's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Marizyme's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Marizyme helps investors to forecast how Marizyme otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Marizyme more accurately as focusing exclusively on Marizyme's fundamentals will not take into account other important factors: Marizyme OTC Stock Current Valuation Analysis
Marizyme's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Marizyme Current Valuation | 17.35 M |
Most of Marizyme's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marizyme is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Marizyme has a Current Valuation of 17.35 M. This is 99.88% lower than that of the Software sector and 99.63% lower than that of the Information Technology industry. The current valuation for all United States stocks is 99.9% higher than that of the company.
Marizyme Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marizyme's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Marizyme could also be used in its relative valuation, which is a method of valuing Marizyme by comparing valuation metrics of similar companies.Marizyme is currently under evaluation in current valuation category among its peers.
Marizyme Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (180.85) % | |||
| Current Valuation | 17.35 M | |||
| Shares Outstanding | 10.13 M | |||
| Shares Owned By Insiders | 2.04 % | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 133.06 X | |||
| Revenue | 210.28 K | |||
| Gross Profit | 129.93 K | |||
| EBITDA | (10.83 M) | |||
| Net Income | (11 M) | |||
| Cash And Equivalents | 2.04 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 495.32 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 1.74 X | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (5.79 M) | |||
| Earnings Per Share | (0.39) X | |||
| Number Of Employees | 11 | |||
| Beta | 0.36 | |||
| Market Capitalization | 5.07 M | |||
| Total Asset | 66 M | |||
| Z Score | 6.0 | |||
| Net Asset | 66 M |
About Marizyme Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marizyme's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marizyme using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marizyme based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.